Hospital
Lexington Medical Center
Lexington Medical Center was paid $15.76M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is 99284, emergency room visit (serious) — 41% of everything it billed.
33Billing provider infoLEXINGTON MEDICAL CENTER
LEXINGTON, NC 27292
LEXINGTON, NC 27292
33aNPI1417958331assigned 08/02/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.76M
24GClaims289,055
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#36 of 92
Median peer was paid$11.47M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,568 | $1.57M | |
| 2019 | 39,628 | $1.45M | |
| 2020 | 24,563 | $724K | |
| 2021 | 37,273 | $1.87M | |
| 2022 | 42,765 | $2.96M | |
| 2023 | 48,371 | $3.26M | |
| 2024incomplete | 45,887 | $3.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 41% | 31,137 | 29,010 | $6.54M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 31,119 | 29,062 | $4.73M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 6.5% | 6,310 | 5,789 | $1.02M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.4% | 25,848 | 22,090 | $694K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.2% | 2,149 | 1,974 | $669K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 3,914 | 3,628 | $220K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 22,692 | 20,584 | $173K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,146 | 2,925 | $134K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,487 | 3,997 | $134K |
| 80053 | Comprehensive metabolic panel | <1% | 15,084 | 13,695 | $133K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,278 | 1,215 | $101K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 120 | 115 | $89K |
102 more codes
| J3490 | Unclassified drugs | <1% | 5,994 | $72K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 279 | $69K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,873 | $64K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,866 | $59K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 978 | $49K |
| G0378 | Hospital observation service, per hour | <1% | 403 | $46K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,351 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,428 | $43K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,428 | $43K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 986 | $39K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 570 | $36K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 625 | $34K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 12 | $30K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,518 | $29K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 968 | $29K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,059 | $29K |
| 97597 | <1% | 718 | $28K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 395 | $27K |
| 81025 | <1% | 3,075 | $26K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,261 | $22K |
| A9270 | Non-covered item or service | <1% | 57,465 | $21K |
| 85027 | <1% | 3,071 | $21K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 262 | $18K |
| 87430 | <1% | 932 | $16K | |
| 81001 | <1% | 4,472 | $15K | |
| 83690 | <1% | 1,722 | $13K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 352 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 248 | $11K |
| 87631 | <1% | 131 | $10K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 92 | $9K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 41 | $8K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,157 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 161 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,474 | $7K |
| 69210 | <1% | 224 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 462 | $7K |
| 86803 | <1% | 312 | $6K | |
| 81002 | <1% | 2,060 | $6K | |
| 84484 | <1% | 578 | $6K | |
| 86850 | <1% | 279 | $6K | |
| 86592 | <1% | 1,027 | $5K | |
| 92567 | <1% | 235 | $5K | |
| 87088 | <1% | 486 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 81 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 371 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 565 | $4K |
| 86762 | <1% | 209 | $4K | |
| 81003 | <1% | 1,742 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 315 | $4K |
| 87340 | <1% | 277 | $4K | |
| 86787 | <1% | 198 | $3K | |
| 83735 | <1% | 454 | $3K | |
| 87632 | <1% | 22 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 419 | $3K |
| 87070 | <1% | 234 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 667 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 220 | $2K |
| 86900 | <1% | 291 | $2K | |
| 86901 | <1% | 291 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 737 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 110 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 352 | $2K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 98 | $2K |
| 31231 | <1% | 26 | $2K | |
| 0001A | <1% | 24 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 738 | $1K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $998.29 |
| 83655 | <1% | 60 | $877.69 | |
| 0002A | <1% | 14 | $780.00 | |
| 88142 | <1% | 28 | $779.11 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $745.90 |
| 82950 | <1% | 114 | $736.85 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 22 | $736.66 |
| 87486 | <1% | 22 | $736.66 | |
| 87081 | <1% | 69 | $657.89 | |
| 80061 | Lipid panel | <1% | 58 | $601.20 |
| Q3014 | Telehealth originating site facility fee | <1% | 125 | $561.38 |
| 83605 | <1% | 68 | $534.90 | |
| 83020 | <1% | 26 | $524.24 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 83 | $503.82 |
| 90686 | <1% | 29 | $375.10 | |
| 82105 | <1% | 12 | $352.60 | |
| 82248 | <1% | 55 | $294.42 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 12 | $241.56 |
| J2704 | Injection, propofol, 10 mg | <1% | 59 | $212.39 |
| 82947 | <1% | 50 | $208.70 | |
| 80076 | <1% | 20 | $205.56 | |
| 86738 | <1% | 22 | $202.57 | |
| 84702 | <1% | 16 | $183.48 | |
| 96127 | <1% | 19 | $168.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 48 | $105.63 |
| 82728 | <1% | 14 | $89.85 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $83.82 |
| 84466 | <1% | 14 | $79.55 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 15 | $43.05 |
| 83540 | <1% | 14 | $40.40 | |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | <1% | 12 | $32.08 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 12 | $23.03 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 79 | $0.00 |
| 91300 | 0% | 44 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 12 | $0.00 |
| 91301 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWN, CHAD (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| WRMC Hospital Operating Corporation | North Wilkesboro, NC | $9.43M |
| Davie Medical Center | Bermuda Run, NC | $818K |
| The Dental Office PC | Sheldon, IA | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.